The FDA has approved Gilead Sciences' Epclusa to treat adults with chronic hepatitis C, both with and without cirrhosis.
Here are four observations:
1. Epclusa is a fixed-dose combination tablet.
2. The drug is approved for use in combination with ribavirin for patients with moderate to severe cirrhosis.
3. Epclusa's most common side effects are headache and fatigue.
4. Gilead Sciences has courted controversy in the past. The company's Sovaldi and Harvoni drugs, also intended for HCV treatment, were criticized for their high prices.